IGI Nominates ISB 2301 as Drug Candidate Targeting Solid Tumors Ahead of 2026 IND Filing

IGI's nomination of ISB 2301 as a drug candidate for solid tumors sets a defined regulatory clock in motion: an IND submission is targeted before year-end 2026, with first-in-human clinical studies planned for 2027. For development operations and regulatory affairs teams tracking Indian biopharma pipeline activity, the timeline signals an active pre-IND package now in preparation.

Candidate nomination marks the transition from discovery to formal development, triggering the preclinical data packages, pharmacology, toxicology, CMC, required to support an IND filing under applicable regulatory frameworks. The compressed window between nomination and intended IND submission suggests preclinical work is substantially advanced, though no data have been disclosed publicly at this stage.

For QA and regulatory leads benchmarking oncology pipeline velocity across Indian biopharma, ISB 2301 represents an early-stage solid tumor program moving toward the clinic on an accelerated internal schedule. Solid tumor indications carry well-documented complexity in patient stratification, endpoint selection, and manufacturing requirements for biologic or small-molecule candidates, details that will become material once the IND is filed and trial design is disclosed.

The 2027 first-in-human target places ISB 2301 within a competitive window for solid tumor therapeutics, where clinical proof-of-concept timelines routinely extend two to four years beyond Phase 1 initiation. Regulatory affairs teams monitoring the IND submission cycle will have a clearer read on program scope once the filing is made and study design parameters are available.

The IND submission, if filed on schedule by end of 2026, will serve as the first measurable checkpoint for ISB 2301's progression toward clinical evaluation.

Source: Indian Pharma Post via Media4Growth, 19 May 2026.